An alternative to opiods? Scientists at the University of Utah have found a compound that blocks pain by targeting a pathway not associated with opioids. Research in rodents indicates that the benefits continue long after the compound have cleared the body.
The findings were reported online in the February 20 issue of the Proceedings of the National Academy of Sciences.
The opioid crisis has reached epidemic proportions. Opioids is highly addictive and according to the Centers for Disease Control and Prevention, 91 Americans die every day from an opioid overdose. The medical community is in need of alternative therapies that do not rely on the opioid pathways to relieve pain.
“Nature has evolved molecules that are extremely sophisticated and can have unexpected applications,” begins Baldomero Olivera, professor in biology at the University of Utah. “We were interested in using venoms to understand different pathways in the nervous system.”
Conus regius, a small marine cone snail common to the Caribbean Sea, packs a venomous punch, capable of paralyzing and killing its prey.
In this study, the researchers found that a compound isolated from snail’s venom, Rg1A, acts on a pain pathway distinct from that targeted by opioid drugs. Using rodent models, the scientists showed that a9a10 nicotinic acetylcholine receptors (nAChR) functions as a pain pathway receptor and that RgIA4 is an effective compound to block this receptor. The pathway adds to a small number of nonopioid-based pathways that could be further developed to treat chronic pain.
Interestingly, the duration of the pain relief is long, greatly outlasting the presence of the compound in the animal’s system.
The compound works its way through the body in 4 hours, but the scientists found the beneficial effects lingered. “We found that the compound was still working 72 hours after the injection, still preventing pain,” said J. Michael McIntosh, professor of psychiatry at the University of Utah Health Sciences. The duration of the outcome may suggest that the snail compound has a restorative effect on some components of the nervous system.
“What is particularly exciting about these results is the aspect of prevention,” said McIntosh. “Once chronic pain has developed, it is difficult to treat. This compound offers a potential new pathway to prevent chronic pain from developing in the first place and also offers a new therapy to patients with established pain who have run out of options.”
The researchers will continue to the next step of pre-clinical testing to investigate the safety and effectiveness of a new drug therapy.
Testing a new nonopioid compound
Previous research had shown that RgIA was effective in rodents, but the scientists wanted to ensure they had a compound that would work in people. To do this, they used synthetic chemistry to engineer 20 analogs of the compound. In essence, the scientists started with a key (RgIA) that fits into a lock (the pain pathway receptor a9a10 nAChR). Using the key as a template, they developed new keys (analogs) with slightly different configurations.
The scientists found one key that best fit the lock: the analog RgIA4 tightly bound to the human receptor.
To test whether the compound relieved pain, the scientists administered it to rodents that were exposed to a chemotherapy drug that causes extreme cold sensitivity, as well as hypersensitivity to touch. “Interactions that are not normally painful, like sheets rubbing against the body or pants against the leg, becomes painful,” said McIntosh.
While the untreated rodents experienced pain after exposure to the chemotherapy drug, rodents given the compound did not experience pain. Nor did rodents that were genetically altered rodents to lack the pain pathway receptor. This work demonstrates that a9a10 nAChR acts as a pain pathway receptor, and that RgIA4 prevents the receptor from being activated.
Most pain medications available today work through a limited number of pathways and are not sufficient to alleviate chronic pain. “RgIA4 works by an entirely new pathway, which opens the door for new opportunities to treat pain,” said McIntosh. “We feel that drugs that work by this pathway may reduce burden of opioid use.”
Receive an email update when we add a new PAIN article.
The Latest on: Pain relief
via Google News
The Latest on: Pain relief
- Opioid Withdrawal Treatment Market - Overview Global Trends 2028 | Teva Pharmaceutical Industries Ltd, Pfizer Incon January 23, 2020 at 5:33 pm
Jan 24, 2020 (The Expresswire) -- The global market for opioid withdrawal treatment is expected to witness moderate growth over the forecast period. Opioids are drugs which are used to treat pain ...
- Treatment for low back pain in older adults does not match guidelineson January 23, 2020 at 10:57 am
Low back pain is a common reason for healthcare visits - in a given year, about ten percent of people will develop a new episode of LBP. Studies examining trends in LBP treatment found increasing use ...
- Getting Relief from Heel Painon January 23, 2020 at 10:32 am
Whether you’re super active or more of a couch potato, young or old, heel pain can affect anyone. And if it’s persistent, you don’t want to ignore it. Let the experts do an assessment and get you back ...
- For low back pain in older adults, treatment doesn't match guidelineson January 23, 2020 at 9:59 am
Low back pain is a common reason for healthcare visits—in a given year, about ten percent of people will develop a new episode of LBP. Studies examining trends in LBP treatment found increasing use of ...
- First treatment for pain using human stem cells a successon January 23, 2020 at 7:04 am
Researchers at the University of Sydney have used human stem cells to make pain-killing neurons that provide lasting relief in mice, without side effects, in a single treatment. The next step is to ...
- Blue Cross Blue Shield of Massachusetts Covers Innovative, Non-Surgical Treatment For Members With Knee, Low Back Painon January 23, 2020 at 4:01 am
Pilot program will measure efficacy of the AposTherapy® biomechanical shoe in reducing pain, improving quality of life without surgery BOSTON, Jan. 23, 2020 /PRNewswire/ -- Blue Cross Blue Shield of ...
- DTM™ Spinal Cord Stimulation Using the Medtronic Intellis™ Platform Shows Superior Back Pain Relief Compared to Conventional SCS Therapy in an RCTon January 21, 2020 at 2:07 pm
At Three-Months, 80% of Patients Treated with DTM SCS Reported Back Pain Reliefof at Least 50%; 63% Reported Profound Back Pain Relief of 80% or Greater1 DUBLIN, Jan. 21, ...
- Research Casts Doubt on Cannabis as a Reliable Pain and Insomnia Treatmenton January 21, 2020 at 1:56 pm
“We do not have a body of organized research with cannabis when it comes to cancer care in general, whether that’s cancer treatment, whether that’s cancer pain management; whether that’s cancer ...
- Study of Sprint Peripheral Nerve Stimulation System Demonstrates 12 Months of Low Back Pain Relief Following 60-Day Treatmenton January 21, 2020 at 4:55 am
CLEVELAND, Jan. 21, 2020 (GLOBE NEWSWIRE) -- SPR Therapeutics, Inc., a leader in neurostimulation technology for pain management, today announced publication of a prospective case series regarding its ...
via Bing News